Evommune, Inc. (EVMN)

NYSE: EVMN · Real-Time Price · USD

11.18

-0.29 (-2.53%)

Jul 28, 2026, 12:34 PM EDT - Market open

Evommune Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	10	13	7	5
Revenue Growth	233.33%	85.71%	40.00%	-
Gross Profit	10	13	7	5
Operating Income	-89.99	-81.07	-70.01	-37.85
Net Income	-75.99	-68.87	-68.31	-34.05
Earnings Per Share	-18.95	-11.22	-45.29	-27.17
EPS Growth	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Investments	211.46	149.2	72.04	79.08
Total Debt	8.02	1.53	0.49	1.26
Net Cash (Debt)	203.44	147.67	71.55	77.83
Net Cash Growth	322.67%	106.38%	-8.06%	-
Net Cash Per Share	14.39	24.06	47.44	62.10

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Cash Flow	-80.05	-76.44	-58.2	-29.97
Capital Expenditures	-	-0.24	-0.09	-0.12
Free Cash Flow	-80.05	-76.68	-58.28	-30.09
Free Cash Flow Growth	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Gross Margin	100.00%	100.00%	100.00%	100.00%
Operating Margin	-899.92%	-623.62%	-1000.19%	-757.00%
Pretax Margin	-759.87%	-529.77%	-954.40%	-681.06%
Profit Margin	-759.87%	-529.77%	-954.40%	-681.06%
FCF Margin	-800.45%	-589.82%	-832.61%	-601.76%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	Jul '26 Jul 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
PS Ratio	41.31	41.51	-	-